The proposed bill, titled the "Right to Try Individualized Investigational Treatment Act," aims to provide patients with life-threatening or severely debilitating illnesses access to individualized investigational treatments. It establishes a new subchapter in the Arkansas Code that outlines the definitions, eligibility criteria, and procedures for patients seeking such treatments. Key definitions include "individualized investigational treatment," which refers to drugs or devices tailored to an individual’s genetic profile, and "eligible patient," who must meet specific medical criteria and provide informed consent. The bill also details the responsibilities of physicians in documenting patient eligibility and the consent process.

Additionally, the bill addresses the availability and costs associated with these treatments, stating that manufacturers may offer treatments without compensation or charge patients for the associated costs. It clarifies that insurance companies are not required to cover these treatments but cannot deny coverage for services otherwise included in insurance contracts. The legislation also includes provisions to protect medical professionals from sanctions related to recommending these treatments and grants immunity from civil liability for those involved in the care of patients receiving individualized investigational treatments, provided they comply with the law.